Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Dasatinib in the First-line Treatment of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Conditions
Interventions
Dasatinib Tablets
Locations
4
China
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong, China
Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital, Medical College , Zhejiang University
Hangzhou, Zhejiang, China
Start Date
May 10, 2016
Primary Completion Date
October 22, 2018
Completion Date
December 6, 2019
Last Updated
June 14, 2021
NCT05794880
NCT03842696
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions